Publications 2002

Becher H., Benner A.: A comparison of three methods to model non-proportional hazards with application to infant mortality in twins. Inf.Biom.Epidem.Med.Biol. 33(2-3), 267-268. 2002.

Benner A.: Application of 'Aggregated Classifiers' in survival time studies. Härdle W. & Rönz B. 171-176. 2002. Heidelberg, Physica. COMPSTAT. Proceedings in Computational Statistics.

Beyer K.S., Klauck S.M., Benner A., Poustka F., Poustka A.: Association studies of the HOPA dodecamer duplication variant in different subtypes of autism. Am.J.Med.Genet. 114 (2002) 110-115.

Breitkreutz I., Glasmacher A., Cremer F.W., Benner A., Schmidt-Wolf I.G.H., Imbach U., Herrmann D., Ho A.D., Goldschmidt H.: Peripheral blood stem cell (PBSC) collection in the treatment of multiple myeloma (MM): influence of VAD and VID. Onkol. 25(S4), 211 (Abstr.No.747). 2002.

Breitkreutz I., Cremer F.W., Benner A., Raab M.S., Möhler T., Christensen O., Herrmann D., Ho A.D., Goldschmidt H.: Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: no influence of previous thalidomide (THAL) administration. Onkol. 25(S4), 211-212 (Abstr.No.748). 2002.

Buchholz E., Drings P., Braun L., Meurer S., Pilz L., Manegold C.: Standard (SCT) versus dose-intensified chemotherapy (ICT) with sequential re-infusion of peripheral blood cells (PBC) in SCLC. J.Cancer Res.Clin.Oncol. 128 (2002) 76 (P386).

Burkholder I., Kopp-Schneider A.: Incorporating phenotype-dependent growth rates into the color-shift model for preneoplastic hepatocellular lesions. Math.Biosci. 179 (2002) 145-160.

Cochlovius B., Stassar M.J.J.G., Schreurs M.W., Benner A., Adema G.J.: Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol.Lett. 80 (2002) 89-96.

Cremer F.W., Bouko Y., Everaert T., Lipinski E., Samson D., Apperely J.F., Thielemans K., Van Camp B., Benner A., Goldschmidt H., Moos M., Bakkus M.H.C.: Quantitation of the post-transplantation tumor load in the bone marrow by PCR with allele-specific oligonucleotide primers is a prognostic parameter in multiple myeloma. Onkol. 25(S4), 120 (Abstr.No.419). 2002.

Dally H., Gassner K., Jäger B., Schmezer P., Spiegelhalder B., Edler L., Drings P., Dienemann H., Schulz V., Kayser K., Bartsch H., Risch A.: Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int.J.Cancer 102 (2002) 530-535.

Deichmann M., Thome M., Benner A., Egner U., Hartschuh W., Naeher H.: PTEN/MMAC1 expression in melanoma resection specimens. Brit.J.Cancer 87 (2002) 1431-1436.

Dencausse Y., Hartung G., Sturm J., Kopp-Schneider A., Hagmüller E., Wojatschek C., Lindemann H., Fritze D., Queisser W.: Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkol. 25 (2002) 426-430.

Dittrich C., Arndt D., Beck J., Behringer D., Berdel W., Bokemeyer C., Borner M., DeSantis M., Edler L., Eisenbrand G., Fichtner I., Fiebig H.H., Fricker G., Gastl G., Hartung G., Hofheinz R., Hossfeld D.K., Illiger H.J., Jaehde U., Keppler B.K., Morant R., Mross K.B., Müller H.J., Oberhoff C., Queisser W., Reichert D., Reszka R., Scheulen M.E., Schüller J., Strumberg D., Pawel J.v., Wiessler M.: CESAR-EWIV: A platform for developing new anticancer agents. J.Cancer Res.Clin.Oncol. 128(Suppl.1), 39 (I199). 2002.

Döhner K., Tobis K., Ulrich R., Fröhling S., Benner A., Schlenk R.F., Döhner H.: Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the AML group Ulm. J.Clin.Oncol. 20 (2002) 3254-3261.

Edler L.: Statistical methods for toxicity detection and testing. In: L.Chyczewski, et al. (Eds.), Endocrine disrupters and carcinogenic risk assessment. IOS Press, Amsterdam, 2002, pp.290-306.

Edler L., Poirier K., Dourson M., Kleiner J., Mileson B., Nordmann H., Renwick A., Slob W., Walton K., Würtzen G.: Mathematical modelling and quantitative methods. Food Chem.Toxicol. 40 (2002) 283-326.

Edler L.: Do new studies of iscador proof efficacy in cancer patients? J.Cancer Res.Clin.Oncol. 128(Suppl.1), 154 (P771). 2002.

Edler L.: Comparing classification methods for protein fold prediction: Support vector machines, neural networks and statistical methods. 39. 2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth International Biometric Conference, July 21-26.

Edler L., Heinzl H.: Exploring the relationships between exposure to PCDDS/FS and neurological health effects in humans. Organohalogen Comp. 57 (2002) 415-418.

Edler L., Geisler I., Rittgen W.: Meeting report. Symposium on mathematical, statistical and computational methods for cancer surveillance and cancer screening. July 27, 2001 Heidelberg, Deutsches Krebsforschungszentrum. J.Cancer Res.Clin.Oncol. 128 (2002) 231-234.

Edler L.: Biometrische Bewertung palliativer Massnahmen. In: D.Fritze (Ed.), Palliative Krebsbehandlung. Beiträge zur interdisziplinären Krebsbehandlung. Zuckschwerdt, München, 2002, pp.7-25.

Edler L., Pilz L.: Klinische Studien. In: C.Manegold (Ed.), Therapieoptionen beim nicht-kleinzelligen Bronchialkarzinom. UNI-MED, Bremen, 2002, pp.153-163.

Edler L.: Anforderungen an die klinische Therapieforschung in der Phase I, II und III. Onkol. 25 (2002) 78-83.

Fischer L., Cardenas C., Thorn M., Benner A., Grenacher L., Vetter M., Lehnert T., Klar E., Meinzer H.P., Lamade W.: Limits of Couinaud's liver segment classification: a quantitative computer-based three-dimensional analysis. J.Comput.Assist.Tomogr. 26 (2002) 962-967.

Fröhling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Döhner H., Döhner K.: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm. Blood 100 (2002) 4372-4380.

Fröhling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Döhner H., Döhner K.: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm. Onkol. 25(S4), 218 (Abstr.No.769). 2002.

Geisler I., Kopp-Schneider A.: Modeling the formation and growth of radiation induced liver focal lesions. 68-69. 2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth International Biometric Conference, July 21-26.

Hamann U., Liu X., Lange S., Ulmer H.U., Benner A., Scott R.J.: Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany. J.Med.Genet. 39 (2002) E12.

Heinzl H., Edler L.: Assessing uncertainty in a toxicokinetic model for human lifetime exposure to TCDD. Organohalogen Comp. 59 (2002) 355-358.

Hofheinz R., Hartung G., Samel S., Emig M., Pilz L., Willecke F., Hochhaus A., Hehlmann R., Queisser W.: Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer. A phase II study. Anticancer Drugs 13 (2002) 999-1004.

Hofheinz R., Hartung G., Samel S., Hochhaus A., Hehlmann R., Pilz L., Queisser W.: Second-line treatment of advanced colorectal cancer with irinotecan, 24-hour high-dose 5-fluorouracil (HD-5-FU) and folinic acid (FA) after failure for HD-5-FU/FA. J.Cancer Res.Clin.Oncol. 128 (2002) P408-S.80.

Hofheinz R.D., Wenz F., Willecke F., Post S., Edler L., Hartung G., Hochhaus A.: Randomized phase III study of adjuvant radiochemotherapy with Capecitabine versus 5-Fluorouracil (5-FU) in rectal carcinoma. Onkol. 25(6), 593. 2002.

Hofmann U., Szedlak M., Rittgen W., Jung E.G., Schadendorf D.: Primary staging and follow-up in melanoma patients - monocenter evaluation of methods, costs and patient survival. Brit.J.Cancer 87 (2002) 151-157.

Höpfner S., Görner M., Benner A., Ho A.D.: Non-myeloablative transplantation - comparison of related versus unrelated donors. Onkol. 25(S4), 97 (Abstr.No.336). 2002.

Ittrich C., Kopp-Schneider A.: Statistical analysis of an interlaboratory prevalidation study. 153. 2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth International Biometric Conference, July 21-26.

Kim B.S., Park J.J., Edler L., v.Fournier D., Haase W., Sautter-Bihl M.L., Gotzes F., Thielmann H.W.: New measure of DNA repair in the single-cell gel electrophoresis (Comet) assay. Environ.Mol.Mutagen. 40 (2002) 50-56.

Klaes R., Benner A., Friedrich T., Ridder R., Herrington S., Jenkins D., Kurman R.J., Schmidt D., Stoler M., Knebel-Döberitz M.v.: p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am.J.Surg.Pathol. 26 (2002) 1389-1399.

Kopp-Schneider A., Geisler I., Edler L.: Complex mechanistic carcinogenicity modeling. In: Endocrine disrupters and carcinogenic risk assessment. IOS Press, 2002, pp.317-328.

Kopp-Schneider A.: Mechanistic carcinogenesis models in quantitative risk assessment: potentials and limitations. 5-6. 2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth International Biometric Conference, July 21-26.

Korz C., Pscherer A., Benner A., Mertens D.: Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 99 (2002) 4554-4561.

Kröber A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., Döhner H., Stilgenbauer S.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (2002) 1410-1416.

Kuntz C., Kienle P., Schmeding M., Benner A., Autschbach F., Schwalbach P.: Comparison of laparoscopic versus conventional technique in colonic and liver resection in a tumor-bearing small animal model. Surg.Endosc. 16 (2002) 1175-11891.

Laack E., Nikbakht H., Peters A., Kugler C., Jasiewicz Y., Edler L., Hossfeld D.K., Schumacher U.: Lectin histochemistry of resected adenocarcinoma of the lung. Helix pomatia agglutinin binding is an independent prognostic factor. Am.J.Pathol. 160 (2002) 1001-1008.

Laack E., Mende T., Dürk H., Kneba M., Dickgreber N., Welte T., Müller T., Scholtze J., Graeven U., Jasiewicz Y., Edler L., Hossfeld D.K.: Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Europ.J.Cancer 38 (2002) 654-660.

Laack E., Nikbakht H., Peters A., Kugler C., Jasiewicz Y., Edler L., Brümmer J., Schumacher U., Hossfeld D.K.: Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J.Clin.Oncol. 20 (2002) 4279-4284.

Lausen B., Benner A.: The assessment of prognostic factors based on micro array data in clinical research. Inf.Biom.Epidem.Med.Biol. 33(2-3), 138. 2002.

Leupolt E., Stilgenbauer S., Kröber A., Benner A., Lichter P., Döhner H.: Clonal evolution in B-CLL-association with IgVH homology, disease progression and in-vivo resistance to therapy. Onkol. 25(S4), 172 (Abstr.No.608). 2002.

Li Y., Hacker H.J., Kopp-Schneider A., Protzer U., Bannasch P.: Woodchuck hepatitis virus replication and antigen expression gradually decrease in preneoplastic hepatocellular lineages. J.Hepatol. 37 (2002) 478.

Liebisch P., Wellmann A., Wendl C., Roth K., Benner A., Stilgenbauer S., Döhner H.: Trisomies of chromosomes 1q, 9q, and 11q in multiple myeloma - non-random distribution of three highly frequent aberrations. Onkol. 25(S4), 73-74 (Abstr.No.252). 2002.

Lutz W.K., Vamvakas S., Kopp-Schneider A., Schlatter J., Stopper H.: Deviation from additivity in mixture toxicity: relevance of nonlinear dose-response relationships and cell line differences in genotoxicity assays with combinations of chemical mutagens and y-radiation. Environ.Hlth.Persp. 110 (2002) 915-918.

Manegold C., Pilz L., Koschel G., Schott K., Hruska D., Mezger J.: Survival data from two randomized phase II studies show effectiveness for therapy of advanced NSCLC by single agent gemcitabine and docetaxel given sequentially in various doses and schedules. J.Cancer Res.Clin.Oncol. 128 (2002) 74 (P376).

Manegold C., Pilz L., Koschel G., Schott K., Hruska D., Mezger J.: Final results from two randomized phase II studies with single agent gemcitabine and docetaxel given sequentially in various doses and schedules are effective in advanced NSCLC. Proc.ASCO (Abstr.No 1273). 2002.

Müller A., Drings P., Rittgen W., Manegold C.: CNS-relapse after multimodality treatment of stage III non-small cell lung cancer. J.Cancer Res.Clin.Oncol. 128 (2002) 76 (P384).

Neben K., Möhler T.M., Benner A., Krämer A., Egerer G., Ho A.D., Goldschmidt H.: Dose-dependent effect of thalidomide on overall suvival in relapsed multiple myeloma. Clin.Cancer Res. 8 (2002) 3377-3382.

Salowsky R., Heiss N.S., Benner A., Wittig R., Poustka A.: Basal transcription activity of the dyskeratosis congenita gene is mediated by Sp1 and Sp3 and a patient mutation in a Sp1 binding site is associated with decreased promoter activity. Gene 293 (2002) 9-19.

Stilgenbauer S., Benner A., Kröber A., Winkler D., Kienle D., Lichter P., Döhner H.: Molecular genetics of CLL: role for future treatment strategies. Onkol. 25(S4), 273 (Abstr.No.978). 2002.

Strieth S., Hartschuh W., Pilz L., Fusenig N.E.: Carcinoma-like vascular density in atypic keratoacanthoma suggests malignant progression. Brit.J.Cancer 87 (2002) 1301-1307.

Tobis K., Fröhling S., Hein S., Benner A., Schlenk R.F., Döhner H., Döhner K.: Partial tandem duplication of the MLL gene as an important prognostic factor for remission duration in adult patients (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study within the multicenter treatment trials AML HD93 and HD98-A of the AML study group Ulm (AMLSG ULM). Onkol. 25(S4), 222 (Abstr.No.785). 2002.

to top